EMAIL FORMAT FOR COMPLAINT:
To: drugshortages@dra.gov.pk
CC: ceo@dra.gov.pk ; pio@dra.gov.pk
Government of Pakistan
Ministry of National Health Services, Regulations and Coordination
(Drug Regulatory Authority of Pakistan)
TF Complex Sector G-9.
Lahore Office:
6-BirdWood Road
Lahore
Phone: +92-42-99203335
SUBJECT: FORMAL COMPLAINT SEEKING URGENT INTERVENTION INTO THE CONTINUED UNAVAILABILITY AND ALLEGED BLACK-MARKET SALE OF APIDRA SOLOSTAR
We, the undersigned, hereby express our grave concern and bring to your immediate attention the continued unavailability of Apidra SoloStar (insulin glulisine) in the market since [INSERT DATE]. This complaint is being submitted to seek urgent intervention into a matter that directly affects the health, well-being and continued medical care of patients who rely upon this medication for the management of their condition.
It is submitted that patients who have been prescribed Apidra SoloStar have experienced difficulties in maintaining adequate disease management following its unavailability. The alternative insulin preparations currently available in the market, including [INSERT NAME(S) OF ALTERNATIVE INSULIN PREPARATIONS], have reportedly failed to produce comparable therapeutic outcomes for certain patients. In particular, [INSERT DETAILS OF THE PATIENTS’ MEDICAL CONDITIONS, THE RELEVANT TREATMENT HISTORY, THE OBSERVED EFFECTS OF ALTERNATIVE PREPARATIONS AND ANY DOCUMENTED ADVERSE OUTCOMES]. These circumstances warrant urgent attention, given that interruptions in access to prescribed insulin and difficulties in achieving adequate glycaemic control may expose patients to serious health risks. Individual treatment decisions, including any change in insulin preparation, must remain under the supervision of the treating medical practitioner.
Of equal concern are reports that Apidra SoloStar is being sold through unofficial channels at prices exceeding twice its usual retail price, as evidenced by the accompanying documentary material [ATTACH PROOF OF PRICING, INCLUDING PHOTOGRAPHS, RECEIPTS, SCREENSHOTS OR OTHER RELEVANT RECORDS]. Such alleged practices raise serious concerns regarding possible hoarding, profiteering, the diversion of available stock into unauthorised channels and the exploitation of patients who have little practical choice but to seek access to a medically necessary product. The circumstances warrant an immediate investigation into the supply chain, the availability of existing stock, the pricing of the product and the conduct of any distributors, retailers or other persons found to be responsible.
We/I call upon, the DRAP to promptly and urgently:
We, the undersigned, are submitting this formal public complaint in the interest of serious public health concerns. We expect the competent authorities and all responsible stakeholders to treat this matter with the urgency it warrants and to take prompt, verifiable and effective action to restore regular access to Apidra SoloStar at lawful prices.
Yours faithfully,
Names: [INSERT NAMES] [CONTACT NUMBER]
Date: [] October 2026
Place: Lahore, Pakistan.